Patient-Perceived Benefit of Treatment in Polypoidal Choroidal Vasculopathy: A Pilot Study

Rituparna Ghoshal, Sharanjeet Sharanjeet-Kaur, Norliza Mohamad Fadzil, Somnath Ghosh, Nor Fariza Ngah and Roslin Azni Abd Aziz
Additional contact information
Rituparna Ghoshal: Optometry and Vision Science Program, Faculty of Health Sciences, University Kebangsaan Malaysia, Kuala Lumpur 50300, Malaysia
Sharanjeet Sharanjeet-Kaur: Optometry and Vision Science Program, Faculty of Health Sciences, University Kebangsaan Malaysia, Kuala Lumpur 50300, Malaysia
Norliza Mohamad Fadzil: Optometry and Vision Science Program, Faculty of Health Sciences, University Kebangsaan Malaysia, Kuala Lumpur 50300, Malaysia
Somnath Ghosh: Department of Allied Health Sciences, Brainware University, Barasat, Kalkata, West Bengal 700125, India
Nor Fariza Ngah: Department of Ophthalmology, Hospital Shah Alam, Persiaran Kayangan, Seksyen 7, Shah Alam 40000, Selangor, Malaysia
Roslin Azni Abd Aziz: Department of Ophthalmology, Hospital Shah Alam, Persiaran Kayangan, Seksyen 7, Shah Alam 40000, Selangor, Malaysia

IJERPH, 2020, vol. 17, issue 17, 1-9

Abstract: Polypoidal choroidal vasculopathy (PCV), a subtype of neovascular age-related macular degeneration, requires repeated treatment. The objective of this pilot study was to evaluate and compare vision-targeted quality of life (QOL) at baseline and after 6 months of treatment in patients with PCV. Naive PCV patients were recruited. Visual functions assessed were distance visual acuity (DVA), near visual acuity (NVA), contrast sensitivity (CS), reading speed (RS), and QOL at baseline and after 6 months of treatment. Thirty patients (average age of 67.62 ± 8.05 years) revealed mean DVA and NVA improvements of 0.24 logMAR and 0.30 logMAR, respectively. Mean CS and RS improved by 0.39 log contrast and 25.58 words per minute, respectively. The National Eye Institute Visual Function Questionnaire 25 (NEI-VFQ-25) composite score significantly increased from a baseline of 66.73 ± 13.74 to 73.54 ± 14.26. Twenty-eight of the patients showed overall improvement in QOL score by 5 units or more or remained stable. Subscales of NEI-VFQ-25 significantly improved, with general vision, mental health, and role difficulties improving by 10 or more units. The present pilot study reports a significant improvement of QOL in PCV patients after 6 months of treatment, with mental health, role difficulties, social functioning, and distance vision activities being the most improved subscales.

Keywords: polypoidal choroidal vasculopathy; patient-perceived treatment outcome; vision-targeted quality of life (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.mdpi.com/1660-4601/17/17/6378/pdf (application/pdf)
https://www.mdpi.com/1660-4601/17/17/6378/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:17:y:2020:i:17:p:6378-:d:407500

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().